E. Schott
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
- Hepatology 38
- Hepatitis C virus research 23
- Hepatocellular Carcinoma Treatment and Prognosis 13
- Liver Diseases and Immunity 1
- Liver Disease and Transplantation 1
-
- Hepatitis B Virus Studies 6
- Co-authors
- Bruno Sangro (5 shared papers)Olivier Rosmorduc (4 shared papers)Thomas Chung Cheung Yau (2 shared papers)Jaclyn Neely (2 shared papers)James J. Harding (2 shared papers)Damir Begic (2 shared papers)Julien Edeline (2 shared papers)Ann‐Lii Cheng (2 shared papers)
In The Last Decade
E. Schott
40 papers receiving 1.1k citations
E. Schott's Hit Papers
Peers
Comparison fields: 5 of 40
- Hepatology 863
- Oncology 205
- Immunology 42
- Virology 7
- Cancer Research 13
Countries citing papers authored by E. Schott
This map shows the geographic impact of E. Schott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Schott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Schott more than expected).
Fields of papers citing papers by E. Schott
This network shows the impact of papers produced by E. Schott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Schott. The network helps show where E. Schott may publish in the future.
Co-authors
The 25 scholars most cited alongside E. Schott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2019 | 563 |
| 2 | 2017 | 134 | |
| 3 | 2007 | 66 | |
| 4 | 2020 | 53 | |
| 5 | 2017 | 42 | |
| 6 | 2018 | 34 | |
| 7 | 2011 | 19 | |
| 8 | 2022 | 18 | |
| 9 | 2022 | 16 | |
| 10 | 2011 | 15 | |
| 11 | 2019 | 12 | |
| 12 | 2015 | 11 | |
| 13 | 2018 | 10 | |
| 14 | 2011 | 8 | |
| 15 | 2014 | 8 | |
| 16 | 2016 | 7 | |
| 17 | 2016 | 6 | |
| 18 | 2024 | 6 | |
| 19 | Isatoribine, a toll-like receptor 7 agonist, significantly reduced plasma viral load in a clinical proof-of-concept study in patients with chronic hepatitis C virus infection. | 2004 | 5 |
| 20 | 2008 | 5 |
About E. Schott
E. Schott is a scholar working on Hepatology, Epidemiology, Surgery, Immunology and Genetics, having authored 45 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hepatitis C virus research (23 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Hepatitis B Virus Studies (6 papers), Genetic Associations and Epidemiology (1 paper), Organ Transplantation Techniques and Outcomes (1 paper), Liver Diseases and Immunity (1 paper), Immune Response and Inflammation (1 paper) and Liver Disease and Transplantation (1 paper). The work is most often cited by research in Hepatology (863 citations), Oncology (205 citations), Immunology (42 citations), Virology (7 citations) and Cancer Research (13 citations). E. Schott has collaborated with scholars based in Germany, Spain and Austria. Frequent co-authors include Bruno Sangro, Olivier Rosmorduc, Thomas Chung Cheung Yau, Jaclyn Neely, James J. Harding, Damir Begic, Julien Edeline, Ann‐Lii Cheng, Su Pin Choo and Richard S. Finn. Their work appears in journals such as Journal of Hepatology, Annals of Oncology, Journal of Viral Hepatitis, Hepatology and Gastroenterology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.